Regeneron Pharmaceuticals Inc

REGN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
REGN Income Statement
REGN Balance Sheet
REGN Cash Flow
Congress Trading

Recent trades of REGN by members of U.S. Congress

Politician Type Traded
Josh Gottheimer House / D Sale $1,001 - $15,000 Nov. 29, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Nov. 19, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Oct. 23, 2024
Greg Landsman House / D Sale $1,001 - $15,000 Oct. 15, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Jul. 01, 2024
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 Apr. 04, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Feb. 08, 2024
Jonathan L. Jackson House / D Purchase $1,001 - $15,000 Jan. 17, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 Nov. 13, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Aug. 21, 2023
Greg Landsman House / D Purchase $1,001 - $15,000 Aug. 11, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jul. 11, 2023
Jonathan L. Jackson House / D Purchase $15,001 - $50,000 Jun. 23, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Jun. 22, 2023
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 Apr. 03, 2023
Josh Gottheimer House / D Sale $1,001 - $15,000 Mar. 06, 2023
Josh Gottheimer House / D Purchase $1,001 - $15,000 Oct. 19, 2022
Josh Gottheimer House / D Purchase $1,001 - $15,000 Sep. 12, 2022
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 Mar. 30, 2022
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Feb. 28, 2022
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Sep. 17, 2021
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Jul. 21, 2021
Josh Gottheimer House / D Sale $1,001 - $15,000 Jul. 01, 2021
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 Jun. 17, 2021
Josh Gottheimer House / D Sale $1,001 - $15,000 May. 17, 2021
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 Mar. 29, 2021
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jan. 11, 2021
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Dec. 22, 2020
Josh Gottheimer House / D Sale $1,001 - $15,000 Dec. 11, 2020
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Aug. 14, 2020
Donald S. Beyer, Jr. House / D Sale $1,001 - $15,000 Jul. 10, 2020
Josh Gottheimer House / D Purchase $1,001 - $15,000 May. 27, 2020
Donald S. Beyer, Jr. House / D Purchase $1,001 - $15,000 May. 20, 2020
Dean Phillips House / D Sale $1,001 - $15,000 May. 13, 2020
Dean Phillips House / D Sale $1,001 - $15,000 Apr. 02, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 Feb. 20, 2020
Mikie Sherrill House / D Purchase $1,001 - $15,000 Jan. 15, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 Dec. 12, 2019
Josh Gottheimer House / D Purchase $1,001 - $15,000 Nov. 01, 2019
Josh Gottheimer House / D Sale $1,001 - $15,000 Sep. 20, 2019
Thomas R. Suozzi House / D Sale $50,001 - $100,000 Sep. 16, 2019
Dean Phillips House / D Purchase $1,001 - $15,000 Sep. 11, 2019
Thomas R. Suozzi House / D Sale $1,001 - $15,000 Aug. 21, 2019
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Aug. 14, 2019
Dean Phillips House / D Purchase $1,001 - $15,000 Aug. 13, 2019
Dean Phillips House / D Sale $1,001 - $15,000 May. 13, 2019
Thomas R. Suozzi House / D Purchase $50,001 - $100,000 May. 02, 2019
Nicholas V. Taylor House / R Sale $15,001 - $50,000 Mar. 25, 2019
Nicholas V. Taylor House / R Sale $1,001 - $15,000 Mar. 07, 2019
Nicholas V. Taylor House / R Sale $1,001 - $15,000 Feb. 06, 2019
REGN Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
REGN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
REGN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by REGN's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $400,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $400,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $430,000 Apr 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $430,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $400,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $370,000 Jul 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $320,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $320,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $340,000 Jul 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $370,000 Apr 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
  • $370,000 Jan 20, 2022 Issue: None
  • $360,000 Oct 20, 2021 Issue: None
  • $310,000 Jul 20, 2021 Issue: None
  • $330,000 Apr 20, 2021 Issue: None
  • $330,000 Jan 21, 2021 Issue: None
  • $480,000 Oct 20, 2020 Issue: None
  • $320,000 Jul 20, 2020 Issue: None
  • $370,000 Apr 20, 2020 Issue: None
  • $340,000 Jan 21, 2020 Issue: None
  • $180,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
  • $250,000 Jul 22, 2019 Issue: Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues Medicare/Medicaid
  • $300,000 Apr 22, 2019 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $90,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
  • $180,000 Oct 22, 2018 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $190,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
  • $200,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $260,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $120,000 Oct 20, 2017 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
  • $120,000 Jul 20, 2017 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Budget/Appropriations
  • $240,000 Apr 20, 2017 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $130,000 Jan 20, 2017 Issue: Health Issues Medicare/Medicaid
  • $130,000 Oct 20, 2016 Issue: Health Issues
  • $120,000 Jul 20, 2016 Issue: Health Issues
  • $50,000 Apr 19, 2016 Issue: Health Issues
  • $50,000 Jan 16, 2016 Issue: Health Issues
  • $50,000 Oct 20, 2015 Issue: Health Issues
  • $50,000 Jul 20, 2015 Issue: Health Issues
  • $60,000 Apr 20, 2015 Issue: Health Issues
  • $52,000 Jan 19, 2015 Issue: Health Issues
  • $50,000 Oct 20, 2014 Issue: Health Issues
  • $50,000 Jul 21, 2014 Issue: Health Issues
  • $50,000 Jan 22, 2014 Issue: Health Issues
  • $50,000 Oct 21, 2013 Issue: Health Issues
  • $40,000 Jul 22, 2013 Issue: Health Issues
  • $30,000 Apr 24, 2013 Issue: Health Issues
  • $30,000 Feb 02, 2013 Issue: Health Issues
  • $30,000 Oct 31, 2012 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Method of characterization of visible and/or sub-visible particles in biologics Dec. 03, 2024
  • Patent Title: Multimeric protein purity determination Dec. 03, 2024
  • Patent Title: Mitochondrial dna quality control Dec. 03, 2024
  • Patent Title: Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors Dec. 03, 2024
  • Patent Title: Readily isolated bispecific antibodies with native immunoglobulin format Dec. 03, 2024
  • Patent Title: Detection and quantification of glycosylated peptides Dec. 03, 2024
  • Patent Title: Unbiased and high-throughput identification and quantification of host cell protein impurities by automated iterative lc-ms/ms (hcp-aims) for therapeutic protein development Nov. 26, 2024
  • Patent Title: Human antibodies to ebola virus glycoprotein Nov. 26, 2024
  • Patent Title: Method and chromatography system for determining amount and purity of a multimeric protein Nov. 26, 2024
  • Patent Title: Chimeric antigen receptors with bcma specificity and uses thereof Nov. 26, 2024
  • Patent Title: Tubulysins and protein-tubulysin conjugates Nov. 19, 2024
  • Patent Title: Methods of treating urea cycle disorders by interfering with glucagon receptor signaling Nov. 12, 2024
  • Patent Title: Tandem mass tag multiplexed quantitation of post-translational modifications of proteins Nov. 05, 2024
  • Patent Title: Systems and methods for identifying hla-associated tumor peptides Nov. 05, 2024
  • Patent Title: Hydrophilic linkers for antibody drug conjugates Nov. 05, 2024
  • Patent Title: Genetically modified non-human animals and methods of use thereof Oct. 29, 2024
  • Patent Title: Humanized m-csf mice Oct. 29, 2024
  • Patent Title: Heavy peptide approach to accurately measure unprocessed c-terminal lysine Oct. 22, 2024
  • Patent Title: Methods of treating liver diseases with phosphodiesterase 3b (pde3b) inhibitors Oct. 22, 2024
  • Patent Title: Packaging Oct. 22, 2024
  • Patent Title: Identification of host cell proteins Oct. 15, 2024
  • Patent Title: Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf Oct. 15, 2024
  • Patent Title: Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof Oct. 15, 2024
  • Patent Title: Rodents having a humanized tmprss gene Feb. 27, 2024
  • Patent Title: Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof Feb. 20, 2024
  • Patent Title: Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab Feb. 20, 2024
  • Patent Title: Quantitation and identification of dimers in co-formulations Feb. 13, 2024
  • Patent Title: Methods of treating allergy using anti-bet v 1 antibodies Feb. 13, 2024
  • Patent Title: Radiolabeled met binding proteins for immuno-pet imaging and methods of use thereof Feb. 13, 2024
  • Patent Title: Mouse comprising a humanized ttr locus with a beta-slip mutation and methods of use Feb. 06, 2024
  • Patent Title: Methods of treating decreased bone mineral density with cluster of differentiation 109 (cd109) inhibitors Feb. 06, 2024
  • Patent Title: Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis Jan. 30, 2024
  • Patent Title: Ultraviolet monitoring of chromatography performance by orthogonal partial least squares Jan. 30, 2024
  • Patent Title: Antibodies which bind to glucagon-like peptide 1 receptor (glp1r) Jan. 30, 2024
  • Patent Title: Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (ido1) and methods of making and using same Jan. 30, 2024
  • Patent Title: Systems and methods for preparing a polypeptide from a mixture Jan. 30, 2024
  • Patent Title: Therapeutic protein selection in simulated in vivo conditions Jan. 23, 2024
  • Patent Title: Cas-ready mouse embryonic stem cells and mice and uses thereof Jan. 09, 2024
  • Patent Title: Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor Jan. 09, 2024
  • Patent Title: Anti-fgfr2 antibodies and methods of use thereof Jan. 09, 2024
  • Patent Title: Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors Jan. 09, 2024
  • Patent Title: Rotatable surgical table Jan. 09, 2024
  • Patent Title: Methods for quantitating individual antibodies from a mixture Dec. 26, 2023
  • Patent Title: Needle shield grip devices and related methods Dec. 26, 2023
  • Patent Title: Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors Dec. 19, 2023
  • Patent Title: Hsd17b13 variants and uses thereof Dec. 19, 2023
  • Patent Title: Models of tauopathy Dec. 19, 2023
  • Patent Title: Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation Dec. 19, 2023
  • Patent Title: Methods and systems for crispr selection Dec. 19, 2023
  • Patent Title: Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein Dec. 19, 2023
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of REGN in WallStreetBets Daily Discussion

REGN News

Recent insights relating to REGN

CNBC Recommendations

Recent picks made for REGN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in REGN

REGN Top Shareholders
Shareholder
Shares Held
REGN Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

REGN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view REGN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top